Jiangsu Hengrui Pharmaceuticals Co., Ltd.
SEC insider (Form 3/4/5 filer). CIK 0002080343. 10% Owner at Braveheart Bio, Inc. (BRVE) and 1 other issuer. 3 reported Form 4/5 transactions since Sep 2024; latest on Aug 7, 2026. Located in LIANYUNGANG.
Companies Jiangsu Hengrui Pharmaceuticals Co., Ltd. has filed insider reports for
- Braveheart Bio, Inc. (BRVE): 10% Owner
- Kailera Therapeutics, Inc. (KLRA): 10% Owner
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
CIK: 0002080343
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)0 (0.0%)
Compensation grants
Other (G, F, J, C, D, …)3 (100.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
